Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has received an average rating of “Hold” from the thirteen research firms that are presently covering the stock, MarketBeat.com reports. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $17.89.

A number of brokerages have recently issued reports on IRWD. BidaskClub upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Zacks Investment Research upgraded shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, July 17th. Mizuho upped their target price on shares of Ironwood Pharmaceuticals from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, July 4th. ValuEngine upgraded shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Wedbush reiterated a “neutral” rating and set a $13.00 target price on shares of Ironwood Pharmaceuticals in a research report on Friday, June 16th.

In related news, insider Halley E. Gilbert sold 35,000 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $19.75, for a total transaction of $691,250.00. Following the completion of the sale, the insider now directly owns 35,000 shares of the company’s stock, valued at $691,250. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Thomas A. Mccourt sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $18.20, for a total transaction of $546,000.00. Following the sale, the insider now directly owns 30,000 shares of the company’s stock, valued at $546,000. The disclosure for this sale can be found here. Insiders own 7.63% of the company’s stock.

Several large investors have recently bought and sold shares of IRWD. Strs Ohio increased its stake in Ironwood Pharmaceuticals by 132.1% in the first quarter. Strs Ohio now owns 6,500 shares of the biotechnology company’s stock worth $110,000 after buying an additional 3,700 shares during the period. Jane Street Group LLC acquired a new stake in Ironwood Pharmaceuticals during the first quarter worth $194,000. Karp Capital Management Corp acquired a new stake in Ironwood Pharmaceuticals during the first quarter worth $201,000. Raymond James Financial Services Advisors Inc. increased its stake in Ironwood Pharmaceuticals by 8.0% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 12,161 shares of the biotechnology company’s stock worth $207,000 after buying an additional 898 shares during the period. Finally, KCG Holdings Inc. increased its stake in Ironwood Pharmaceuticals by 20.5% in the first quarter. KCG Holdings Inc. now owns 14,270 shares of the biotechnology company’s stock worth $243,000 after buying an additional 2,428 shares during the period. 98.16% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/24/ironwood-pharmaceuticals-inc-irwd-receives-consensus-rating-of-hold-from-analysts.html.

Ironwood Pharmaceuticals (NASDAQ:IRWD) opened at 17.22 on Monday. The firm’s market cap is $2.56 billion. The company’s 50 day moving average is $18.52 and its 200-day moving average is $17.04. Ironwood Pharmaceuticals has a 1-year low of $12.48 and a 1-year high of $19.94.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Monday, May 8th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.14. Ironwood Pharmaceuticals had a negative return on equity of 195.06% and a negative net margin of 46.49%. The company had revenue of $52.16 million for the quarter, compared to analyst estimates of $69.39 million. During the same quarter in the previous year, the company posted ($0.08) earnings per share. Ironwood Pharmaceuticals’s revenue for the quarter was down 21.0% on a year-over-year basis. On average, analysts predict that Ironwood Pharmaceuticals will post ($0.91) EPS for the current fiscal year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.